Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial - Chart
- Upturn Summary
- Highlights
- Valuation
Upturn AI SWOT - About
PASG 
Passage Bio Inc (PASG)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- 1Y
- 1M
- 1W
Upturn Advisory Summary
11/28/2025: PASG (1-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
5 Analysts rated it
Limited analyst coverage, niche firm, research info may be scarce.
1 Year Target Price $39.6
1 Year Target Price $39.6
| 5 | Strong Buy |
| 0 | Buy |
| 0 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit -33.65% | Avg. Invested days 35 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  2.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 11/28/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 28.07M USD | Price to earnings Ratio - | 1Y Target Price 39.6 |
Price to earnings Ratio - | 1Y Target Price 39.6 | ||
Volume (30-day avg) 5 | Beta 1.88 | 52 Weeks Range 5.12 - 20.80 | Updated Date 11/30/2025 |
52 Weeks Range 5.12 - 20.80 | Updated Date 11/30/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -14.62 |
Earnings Date
Report Date 2025-11-18 | When - | Estimate -0.2 | Actual -2.44 |
Profitability
Profit Margin - | Operating Margin (TTM) - |
Management Effectiveness
Return on Assets (TTM) -31.66% | Return on Equity (TTM) -87.18% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value -367991 | Price to Sales(TTM) - |
Enterprise Value -367991 | Price to Sales(TTM) - | ||
Enterprise Value to Revenue - | Enterprise Value to EBITDA 0.87 | Shares Outstanding 3178710 | Shares Floating 2867165 |
Shares Outstanding 3178710 | Shares Floating 2867165 | ||
Percent Insiders 0.21 | Percent Institutions 51.89 |
Upturn AI SWOT
Passage Bio Inc
Company Overview
History and Background
Passage Bio, Inc. was a genetic medicines company focused on developing transformative therapies for rare, monogenic central nervous system (CNS) disorders. Founded in 2017, it went public in 2020. In October 2023 the company was acquired by Neurvati Neurosciences Limited.
Core Business Areas
- Gene Therapy Development: Focused on AAV-delivered gene therapies for rare CNS disorders. This included preclinical and clinical development efforts.
- Research and Development: Conducted research to identify and validate new therapeutic targets in genetic CNS diseases.
- Collaboration: Entered into collaborations with academic institutions and other companies to advance its pipeline.
Leadership and Structure
At time of acquisition: Chief Executive Officer was Dr. Bruce Goldsmith. Company followed typical bio-pharmaceutical structure with research, development, clinical, and commercial divisions.
Top Products and Market Share
Key Offerings
- PBGM01 (GM1 gangliosidosis): An AAVrh10-based gene therapy designed to deliver a functional GLB1 gene to cells in the CNS. Early clinical trials, no market share as product was not approved. Competitors included companies developing therapies for lysosomal storage disorders.
- PBML04 (Metachromatic Leukodystrophy): An AAV delivery of ARSA. Preclinical studies, no market share. Competitors included Orchard Therapeutics who has a treatment approved in Europe
Market Dynamics
Industry Overview
The genetic medicine industry is rapidly growing, driven by advancements in gene therapy technologies and increasing understanding of genetic diseases. Significant investment and regulatory support are fueling this growth, but challenges remain in manufacturing, delivery, and long-term safety.
Positioning
Passage Bio aimed to be a leader in developing AAV-delivered gene therapies for rare CNS disorders. They focused on diseases with unmet medical needs. Passage Bio competed with larger pharmaceutical companies and specialized gene therapy companies.
Total Addressable Market (TAM)
The TAM for gene therapies targeting rare CNS disorders is estimated to be several billion dollars annually. Passage Bio's positioning was aligned with capturing a portion of this TAM by developing first-in-class therapies for specific diseases. Due to it's aquisition in 2023, the company does not have a TAM.
Upturn SWOT Analysis
Strengths
- Proprietary AAV vector technology
- Experienced management team
- Focus on underserved rare disease market
- Strong preclinical data for lead programs
Weaknesses
- High cash burn rate
- Reliance on successful clinical trial outcomes
- Competition from larger pharmaceutical companies
- Regulatory hurdles for gene therapies
Opportunities
- Expanding pipeline through new therapeutic targets
- Securing strategic partnerships
- Accelerated regulatory pathways for rare diseases
- Positive clinical trial results
Threats
- Clinical trial failures
- Adverse events associated with gene therapy
- Competition from novel therapeutic modalities
- Changes in regulatory landscape
Competitors and Market Share
Key Competitors
- BLUE
- ORCH
Competitive Landscape
Passage Bio was smaller than its main competitors, they were focused on niche CNS disorders. The acquisition provides Neurvati Neurosciences with assets and expertise in the gene therapy space.
Major Acquisitions
Neurvati Neurosciences Limited
- Year: 2023
- Acquisition Price (USD millions): 110
- Strategic Rationale: Neurvati acquired Passage Bio to expand its portfolio of neurological disease therapies.
Growth Trajectory and Initiatives
Historical Growth: Growth focused on expanding the clinical trial pipeline and securing funding. Progress was primarily based on R&D activities and clinical trial advancements before acquisition.
Future Projections: Future projections are now tied to Neurvati Neurosciences Limited's strategy for the acquired assets.
Recent Initiatives: Initiated clinical trials for GM1 gangliosidosis, continued preclinical development for other programs. Efforts were made to strengthen partnerships and collaborations.
Summary
Passage Bio was a gene therapy company specializing in rare CNS disorders, that was acquired by Neurvati Neurosciences Limited. While Passage Bio had promising preclinical and clinical data, the acquisition was likely driven by the challenges of funding and navigating the complex regulatory landscape for gene therapies. Neurvati can leverage Passage Bio's assets and expertise to expand its presence in the neurological disease space. It is important to note that the public stock no longer exists.
Similar Stocks
Sources and Disclaimers
Data Sources:
- Company filings
- Analyst reports
- Press releases
- Corporate website
Disclaimers:
The information provided is for informational purposes only and should not be considered financial advice. Investment decisions should be made based on independent research and consultation with a qualified financial advisor. Market share estimates are based on available data and may not be precise. Due to the nature of the acquisition, financial data may not be fully representative of future performance.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Passage Bio Inc
Exchange NASDAQ | Headquaters Philadelphia, PA, United States | ||
IPO Launch date 2020-02-28 | President, CEO & Director Dr. William Chou M.D. | ||
Sector Healthcare | Industry Biotechnology | Full time employees 60 | Website https://www.passagebio.com |
Full time employees 60 | Website https://www.passagebio.com | ||
Passage Bio, Inc., a genetic medicines company, develops gene therapies for central nervous system diseases. It develops PBGM01, a functional GLB1 gene encoding ß-galactosidase for infantile GM1; PBFT02, a functional granulin (GRN) and gene encoding progranulin (PGRN) for the treatment of FTD caused by progranulin deficiency; and PBKR03, a functional GALC gene encoding the hydrolytic enzyme galactosylceramidase for infantile Krabbe disease. The company develops PBML04 for the treatment of metachromatic leukodystrophy; PBAL05 for the treatment of amyotrophic lateral sclerosis; and other program for huntington's disease. It has a strategic research collaboration with the Trustees of the University of Pennsylvania's Gene Therapy Program; and collaboration agreement, and a development services and clinical supply agreement with Catalent Maryland, Inc. The company was incorporated in 2017 and is based in Philadelphia, Pennsylvania.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.